Cibc World Markets Corp Has $1.37 Million Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Cibc World Markets Corp reduced its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 21.2% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 5,810 shares of the biopharmaceutical company’s stock after selling 1,561 shares during the quarter. Cibc World Markets Corp’s holdings in Alnylam Pharmaceuticals were worth $1,367,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the stock. Allworth Financial LP raised its position in shares of Alnylam Pharmaceuticals by 6.8% in the fourth quarter. Allworth Financial LP now owns 597 shares of the biopharmaceutical company’s stock valued at $140,000 after purchasing an additional 38 shares during the period. Nixon Peabody Trust Co. raised its holdings in Alnylam Pharmaceuticals by 1.9% in the 4th quarter. Nixon Peabody Trust Co. now owns 2,293 shares of the biopharmaceutical company’s stock worth $540,000 after acquiring an additional 43 shares during the period. IFP Advisors Inc lifted its position in Alnylam Pharmaceuticals by 24.2% during the 4th quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company’s stock worth $57,000 after acquiring an additional 47 shares during the last quarter. Nwam LLC boosted its holdings in Alnylam Pharmaceuticals by 5.8% during the fourth quarter. Nwam LLC now owns 906 shares of the biopharmaceutical company’s stock valued at $213,000 after acquiring an additional 50 shares during the period. Finally, SYM FINANCIAL Corp grew its position in shares of Alnylam Pharmaceuticals by 6.2% in the third quarter. SYM FINANCIAL Corp now owns 947 shares of the biopharmaceutical company’s stock valued at $260,000 after purchasing an additional 55 shares during the last quarter. Institutional investors own 92.97% of the company’s stock.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 1,213 shares of the business’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $255.17, for a total value of $309,521.21. Following the transaction, the chief executive officer now owns 81,526 shares of the company’s stock, valued at approximately $20,802,989.42. The trade was a 1.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CMO Pushkal Garg sold 52,592 shares of the firm’s stock in a transaction on Monday, January 27th. The shares were sold at an average price of $285.00, for a total value of $14,988,720.00. Following the completion of the sale, the chief marketing officer now owns 11,989 shares of the company’s stock, valued at approximately $3,416,865. This trade represents a 81.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 71,234 shares of company stock worth $19,958,097 in the last three months. Insiders own 1.50% of the company’s stock.

Analysts Set New Price Targets

ALNY has been the subject of several research analyst reports. Morgan Stanley boosted their price objective on Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the stock an “equal weight” rating in a research report on Friday, February 14th. Wells Fargo & Company upped their price target on Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the stock an “equal weight” rating in a report on Friday. Bank of America raised their price objective on shares of Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the stock a “buy” rating in a research note on Friday. Chardan Capital reiterated a “buy” rating and set a $300.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday. Finally, HC Wainwright raised their price target on shares of Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the stock a “buy” rating in a research report on Monday, February 24th. One analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $310.22.

Alnylam Pharmaceuticals Stock Up 11.8 %

Shares of NASDAQ:ALNY opened at $283.34 on Friday. The company’s fifty day moving average is $257.16 and its 200-day moving average is $259.65. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $304.39. The company has a market capitalization of $36.68 billion, a PE ratio of -130.57 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). Equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.